Barinthus Biotherapeutics plc. business relationships
Companies named in Barinthus Biotherapeutics plc.’s 10-K filed 2026-03-13, and public companies whose annual reports name Barinthus Biotherapeutics plc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.2 / 10
- AI naming
- 46 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Barinthus Biotherapeutics plc.’s annual report 2
“For the year ended December 31, 2022, we generated net income of $5.3 million, primarily as a result of revenues (royalties/milestone payments) arising from AstraZeneca sales of Vaxzevria and our agreement with OUI, as amended (the "OUI License Agreement").” SEC filing
“In partnership with Arbutus Biopharma, we presented end-of-study data from the Phase 2a clinical trial (IM-PROVE II, AB-729-202) in CHB evaluating the combination of imdusiran ("IDR"), Arbutus' RNAi therapeutic, followed by VTP-300, with or without LDN.” SEC filing
Links are read automatically from public company filings, so every link carries the sentence it came from.
Not investment advice. Scores, rankings and connections are automated estimates from public sources, provided as is. Connections are read automatically from public company filings and may be incomplete or wrong. To correct or remove a company page or a connection, email [email protected]. Company names and logos belong to their owners. Showing them does not mean the company endorses Engagemii or that Engagemii endorses it. Terms